Abpro(ABPWW)

Focus: Abpro is a public-stage biotechnology company headquartered in New York specializing in antibody development. The company operates at minimal commercial scale with near-zero revenue generation.

Profile data last refreshed 15h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Abpro

AI assessmentNot Hiring

No open roles listed right now. Follow Abpro to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthStrong

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$122K

Recent News · Abpro(1)

FinancialSEC 8-K

Jan 23, 2026

8-K Filing: Abpro Holdings, Inc. (ABP, ABPWW) (CIK 0001893219) — CURRENT REPORT

CURRENT REPORT

Help build intelligence for Abpro

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pure R&D focus with 3497% R&D intensity signals commitment to scientific innovation in antibody therapeutics
Public company status provides equity liquidity and established governance infrastructure absent in private startups
Antibody platform technology offers deep technical expertise in a validated modality with broad therapeutic potential

Watch Out For

Severe financial distress: $122K revenue vs. $4M R&D spend and $11.7M net loss in FY2024 indicates runway concerns
Critically low cash position of $723K in FY2024 creates acute solvency risk and potential for rapid restructuring
Zero active job openings and no disclosed employee count suggest minimal hiring and possible organizational contraction

Generated by Claude from Abpro's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.